Print

Valeant Pharmaceuticals International (VRX) Reports 2012 Third Quarter Financial Results  
11/2/2012 9:42:12 AM

MONTREAL, Nov. 2, 2012 /PRNewswire/ --

• 2012 Third Quarter Total Revenue $884 million
• Organic growth (same store sales) was approximately 14%
• Pro forma organic growth was approximately 12%
• 2012 Third Quarter GAAP EPS $0.02; Cash EPS $1.15

//-->